A human clinical model evaluating acute innate immune response of lenabasum in healthy individuals

Trial Profile

A human clinical model evaluating acute innate immune response of lenabasum in healthy individuals

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Inflammation
  • Focus Pharmacodynamics
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 19 Feb 2018 New trial record
    • 15 Feb 2018 Data from this study were published in "Clinical Pharmacology & Therapeutics", as reported in a Corbus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top